INTRODUCTIONS
The Parker Lab for Applied Proteomics, Personalized Medicine, and HIV Prevention seeks to improve HIV prevention strategies in disproportionately affected communities who are at high risk for HIV transmission. We employ multi-omics, systems biology, immunology and computational approaches to characterize innate immune responses to pathogenic stimuli known to increase HIV risk. This research theme is a culmination of my unique training at the intersection of biomedical engineering, Immunology and Infectious Disease, and Public Health
PRINCIPAL INVESTIGATOR
Dr. Ivana Parker
Dr. Ivana Parker, Ph.D., is a Fulbright Scholar who recently completed a year-long study at the University of Cape Town in South Africa. Her project assesses the risk of a commonly used TB vaccine, BCG, on HIV susceptibility in infants using proteomics and systems biology approaches.